Surely we are nearing the completion of the trial... Or at least close enough that they can stop recruiting and progress to the next stage.
Unfortunately there are over 20,000 new cases of breast cancer in Australia each year equating to 57 per day. 15-20% of these cases are HER2-positive resulting in roughly 4,000 potential patients annually just in Australia. Surely it shouldn't be too hard to enrol 15 participants...
The lack of news is painful for us shareholders, but more-so for current and future breast cancer patients. With the potential life saving technology here you'd think that they want to finish the trials ASAP.
At least we do know that:
It's safe
It reaches the patients lymph nodes
It has multiple purposes
C'mon Bob please give everyone an early Christmas present this year!
IBX Price at posting:
2.6¢ Sentiment: Buy Disclosure: Held
